Sadoul J L, Kezachian B, Freychet P
Service de Médecine Interne et d'Endocrinologie (I4), Hôpital Pasteur, CHU de Nice.
Ann Endocrinol (Paris). 1994;54(5):353-8.
A case of hyperthyroidism occurring in a 68 year old man receiving lithium carbonate (1 g/day) for 5 years is reported. The clinical history of the patient, treated for bipolar affective disorder, was remarkable for transient hypothyroidism followed several months later by tremor, increased free thyroxine and triiodothyronine, and decreased TSH levels which led to lithium withdrawal. Two months later, clinical and biological signs were unchanged, Tc99m-scan displayed a homogeneous and increased isotope uptake. In this setting, high levels of autoantibodies against TSH-receptor, and grade I exophthalmos and slightly ocular muscle enlargement at CT-scan favored the diagnosis of Graves' disease (perhaps facilitated by lithium therapy). Carbimazole treatment was effective in controlling hyperthyroidism. Review of the literature disclosed 44 cases of hyperthyroidism occurring in lithium-treated patients. Most of these cases concerned specific thyroid diseases, particularly with an autoimmune mechanism. There is also evidence for an actual role of lithium in increasing intrathyroid iodide pool and for an impact of lithium on the immune system. Thus, the hypothesis that lithium may trigger the development of an autoimmune thyroid disease in predisposed patients deserves further investigation.
报告了一例68岁男性患者,该患者因双相情感障碍接受碳酸锂(1克/天)治疗5年,发生了甲状腺功能亢进症。该患者的临床病史显示,在接受双相情感障碍治疗期间,先是出现短暂性甲状腺功能减退,几个月后出现震颤、游离甲状腺素和三碘甲状腺原氨酸升高,促甲状腺激素水平降低,从而导致停用碳酸锂。两个月后,临床和生物学体征未改变,锝99m扫描显示同位素摄取均匀增加。在此情况下,针对促甲状腺激素受体的自身抗体水平升高,以及CT扫描显示I级突眼和轻度眼肌增大,支持格雷夫斯病的诊断(可能因锂治疗而加重)。卡比马唑治疗有效控制了甲状腺功能亢进症。文献回顾发现44例接受锂治疗的患者发生甲状腺功能亢进症。这些病例大多涉及特定的甲状腺疾病,尤其是具有自身免疫机制的疾病。也有证据表明锂在增加甲状腺内碘池方面具有实际作用,以及锂对免疫系统有影响。因此,锂可能在易感患者中引发自身免疫性甲状腺疾病的假说值得进一步研究。